2022 Q1 Report: Global Trends in Biopharma Transactions
2022 Q1 Report: Global Trends in Biopharma Transactions Each quarter, Locust Walk deal team members compile key statistics and trends […]
Insight, Market Trends
Market Trends
Market Trends, News
Locust Walk Breakthrough Innovation Reports: Oncology IPS-Effector Cell Therapies
Locust Walk Breakthrough Innovation Reports: Oncology IPS-Effector Cell Therapies In this report you can find an overview and analysis of
Market Trends, News
Breakthrough Innovation Reports: Regenerative Medicine iPS-Cell Therapy Investment Insights and Emerging Players
Breakthrough Innovation Reports: Regenerative Medicine iPS-Cell Therapy Investment Insights and Emerging Players In this report you can find an overview
Market Trends, News, Quarterly Reports
2021 Year End Report
2021 Year End Report Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our 2021
Market Trends, News, Quarterly Reports
Bought Not Sold
Bought Not Sold Why So Many Biopharma M&A Transactions Start Out as Aspirational Licensing Deals Authors: Geoff Meyerson, CEO & Co-Founder
Market Trends, Quarterly Reports
2021 Q3 Report: Global Trends in Biopharma Transactions
2021 Q3 Report: Global Trends in Biopharma Transactions Each quarter, Locust Walk deal team members compile key statistics and trends on
Locust Walk Insights, Market Trends
Crossover Evolution: The Evolving Role of the Crossover Financing Round
Crossover Evolution: The Evolving Role of the Crossover Financing Round Authors: Geoff Meyerson, CEO & Co-Founder Brian Coleman, Global Head of Capital
Locust Walk Insights, Market Trends, Quarterly Reports
2021 Q1 Report: Global Trends in Biopharma Transactions
2021 Q1 Report: Global Trends in Biopharma Transactions Each quarter, Locust Walk deal team members compile key statistics and trends on
Market Trends, News, Quarterly Reports
Locust Walk 2020 Year End Report
Locust Walk 2020 Year End Report Each quarter our team at Locust Walk compiles key statistics and trends on strategic
Capital Raising, Market Trends, News
Doubling Down: The Power of Asset Diversification in a Time of Robust Access to Capital
Doubling Down Following up on our recent white paper, Biopharma’s COVID Capital Comeback, here is a look at the greatest risk